Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA, Vey N.
Crit Rev Oncol Hematol. 2022 Mar;171:103607. doi: 10.1016/j.critrevonc.2022.103607. Epub 2022 Jan 31.
Therapy-Related Myeloid Neoplasms.
Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, Hanson CA.
Am J Clin Pathol. 2015 Aug;144(2):207-18. doi: 10.1309/AJCPU1JO2LYTWUAV.
Therapy-related myeloid neoplasms.
Ganser A, Heuser M.
Curr Opin Hematol. 2017 Mar;24(2):152-158. doi: 10.1097/MOH.0000000000000316.
Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea.
Yun J, Song H, Kim SM, Kim S, Kwon SR, Lee YE, Jeong D, Park JH, Kwon S, Yun H, Lee DS.
Hum Genomics. 2023 Feb 23;17(1):13. doi: 10.1186/s40246-023-00458-8.
Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
Lee JW, Oh H, You JY, Lee ES, Lee JH, Song SE, Lee NK, Jung SP, An JS, Cho KR, Kim CY, Park KH.
Eur J Cancer. 2023 Sep;191:112952. doi: 10.1016/j.ejca.2023.112952. Epub 2023 Jun 22.
Lessons learned from therapy-related acute myeloid leukemia.
Kayser S.
Haematologica. 2023 Apr 1;108(4):956-957. doi: 10.3324/haematol.2022.281742.
Therapy-related myeloid leukemia.
Godley LA, Larson RA.
Semin Oncol. 2008 Aug;35(4):418-29. doi: 10.1053/j.seminoncol.2008.04.012.
Therapy-related myeloid neoplasms.
Larson RA.
Haematologica. 2009 Apr;94(4):454-9. doi: 10.3324/haematol.2008.005157.
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP.
Blood Adv. 2022 May 10;6(9):2847-2853. doi: 10.1182/bloodadvances.2021006239.
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
Chantadisai M, Kulkarni HR, Baum RP.
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1390-1398. doi: 10.1007/s00259-020-05127-9. Epub 2020 Nov 27.
